Why Bill Ackman Thinks Valeant Pharmaceuticals Intl Inc. Will Quadruple in 3 Years

Bill Ackman thinks that Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is wildly misunderstood. Is he right?

The Motley Fool

As Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX), one of the firm’s largest investors is coming to its defence: William Ackman, the chief executive of Pershing Square Capital Management.

As of its most recent 13F filing, Pershing Square held nearly 20 million shares of Valeant in its fund, and Mr. Ackman bought another two million shares early last week. Then on Friday morning he hosted a conference call in which he defended Valeant, its accounting, and its business practices.

Mr. Ackman also made a very bold prediction: that Valeant’s U.S.-listed shares would reach US$448 by 2018. Such a target seems a long way off; on the day that he spoke, the company’s shares had sunk below US$100.

So, why is Mr. Ackman so confident? And is his confidence justified?

Finger pointing

Mr. Ackman said that Valeant’s downfall has been due to a number of factors, none of which are related to its business practices.

To start, he said that Valeant’s PR efforts have been awful. In fairness, he does have a point here. Valeant was slow to respond to the accusations leveled against the company; it took five days for the company to give a detailed rebuttal of Andrew Left after he published his scathing report on Valeant and Philidor.

Mr. Ackman also stated that Valeant isn’t well liked by other drug companies mainly because of jealousy. He is certainly right about Valeant’s lack of popularity—the pharmaceutical lobby PhRMA hasn’t even come to the company’s defence. But his claim that jealousy is the primary cause is very dubious.

Finally, Mr. Ackman blamed journalists and the market for misunderstanding Valeant’s business model. Once again, there is an element of truth here. Most people still don’t have a very clear picture of Valeant, but that is primarily because the firm is so complex and secretive.

A similar defence

While appearing on The Business News Network, Jason Donville of Donville Kent Asset Management gave a similar defence of Valeant. He insisted the company’s biggest problem was Mr. Left and indicated that Mr. Left was the one most responsible for Valeant’s slide.

In other words, Mr. Donville was claiming that Valeant is being wildly misunderstood, and that’s why the stock is down.

Why you should stay far away

Mr. Ackman and Mr. Donville are both very accomplished investors with outstanding track records. But in this case it would be very dangerous to follow their advice.

The reason is simple: it’s now obvious that Philidor was overaggressive in selling Valeant’s products. That’s why Valeant, along with some big Pharmacy Benefits Managers, have cut ties with Philidor.

And according to the Wall Street Journal, Valeant was heavily influencing Philidor’s actions. Such allegations could have big consequences for the company. This story is far from over.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

oil pumps at sunset
Energy Stocks

How a $25,000 TFSA Could Fund Your Retirement

Canadians can turn to the TFSA to help provide a meaningful income stream in retirement.

Read more »

Canada day banner background design of flag
Investing

3 of the Best Canadian Stocks to Buy Right Now

These three Canadian stocks are ideal for balancing wealth-creation opportunities with stability and income generation in this uncertain outlook.

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

TFSA Strategy: How to Earn $500 a Month in Tax-Free Dividend Income

Canadians can earn $500 in tax-free dividend income or another desired amount every month using a simple TFSA strategy.

Read more »

coins jump into piggy bank
Energy Stocks

Canadian Natural Resources vs. Enbridge: The Better Dividend Stock to Buy Today

Both CNQ and ENB have impressive payout records, consistently paying and increasing their dividends for decades.

Read more »

doctor uses telehealth
Dividend Stocks

TFSA Investors: This Monthly Dividend Stock Yields 7.6%

This REIT offers investors a monthly yield investors and a regular and frequent passive income stream to supplement their regular…

Read more »

shopper chooses vegetables at grocery store
Dividend Stocks

Loblaw vs. Empire: Which Grocery Stock Would I Choose for Long-Term Growth?

Both grocers benefit from repeat shoppers. I’d give Loblaw the edge for the ways it can earn more from those…

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

2 Canadian Stocks to Buy and Hold for 20 More Years

CP Rail (TSX:CP) and another outstanding Canadian stock that's more than worth holding for many decades.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Dividend Stocks

2 Top TSX ETFs to Buy and Hold in a TFSA Forever

Looking for top TSX ETFs for your TFSA? Explore how VFV and VDY combine U.S. stock exposure and Canadian dividends…

Read more »